Últimas noticias sobre AGM Gr Hldgs (NASDAQ:AGMH) Bolsa

AGM Gr Hldgs

AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.

Sportsman'sSaratoga,Springs,,Utah,,Usa,-,Nov,30,,2024:,Sportsman's,Warehouse

AEHL

AGMH

BIAF

DGLY

GRFS

NCNO

NMAX

QUAD

RAPP

RSLS

SAMG

SBFM

SPWH

STSS

SYRA

Sportsman&#39;s Warehouse sorprende con ingresos y ganancias inesperadas: conoce las cifras que hicieron subir sus acciones.

Acciones de Sportsman&#39;s Warehouse (SPWH) se disparan un 39%; Aquí están 20 acciones moviéndose en premercado

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

AGM Group Holdings Inc. - Class A Ordinary Shares

AGM Group Holdings Inc

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 3.09% Wednesday morning to $62.02, giving back some of the recent gains following its strong first-quarter earnings report.
Despite the pullback, the stock remains up an impressive 115% over the past month as investor enthusiasm around the company's growth story continues.
What To Know: Last week, Hims &amp; Hers <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">reported</a> first-quarter revenue of $586 million, a 111% increase year over year and well above Wall Street expectations.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45406701/super-micro-computer-stock-is-surging-again-whats-going-on">Super Micro Computer Stock Is Surging Again: What&#8217;s Going On?</a>
Earnings per share came in at 20 cents, beating the consensus estimate of 12 cents. The company also reported subscriber growth of 38%, reaching 2.4 million.
While Hims issued a <a href="https://www.benzinga.com/general/health-care/25/05/45208186/hims-hers-health-q1-earnings-revenue-jumps-111-subscribers-up-38-q2-guidance-falls-short-of-estimates-shares-slide">cautious</a> second-quarter revenue forecast of $530 to $550 million, falling short of the $564.6 million analysts had projected, it reaffirmed its full-year guidance and long-term goal of $6.5 billion in annual revenue by 2030.
Last Thursday, the company <a href="https://www.benzinga.com/pressreleases/25/05/b45307801/hims-hers-health-inc-prices-upsized-870-0-million-convertible-senior-notes-offering-to-accelerate-">announced</a> an upsized $870 million convertible note offering due in 2030, aimed at funding international expansion and strategic initiatives. The offering includes capped call features to reduce dilution and carries a conversion price of $70.67.
Read Also: <a href="https://www.benzinga.com/news/25/05/45408603/why-quoin-pharmaceuticals-qnrx-stock-is-exploding-higher-wednesday">Why Quoin Pharmaceuticals Stock Is Exploding Higher Wednesday</a>
<h2 class="wp-block-heading">How To Buy HIMS Stock</h2>
By now you're likely curious about how to participate in the market for Hims &amp; Hers Health &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HIMS has a 52-week high of $72.98 and a 52-week low of $13.47.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month

Dynatrace, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45401623/dynatrace-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results" rel="noreferrer noopener">fourth-quarter 2025</a> results on Wednesday.
The company&nbsp;reported quarterly revenue growth of 17% year-over-year to $445.17 million, beating the analyst consensus estimate of $434.78 million.
Adjusted EPS was $0.33, up from $0.30,&nbsp;beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $0.30.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45357365/salesforce-sales-cloud-ai-integration-and-cloud-upsells-drive-analyst-confidence-in-long-term-growth" target="_blank" rel="noreferrer noopener">Salesforce Sales Cloud, AI Integration, And Cloud Upsells Drive Analyst Confidence In Long-Term Growth</a>
The stock price gained after the report.
Annual Recurring Revenue (ARR) increased by 15% Y/Y or 17% in constant currency. Revenues from Subscription rose 18% Y/Y to $423.57 million.
The adjusted operating margin expanded 100 bps to 26%, with operating income up 24% Y/Y to $117.89 million.
As of March-end, Dynatrace held $1.11 billion in cash and equivalents.
During the fourth quarter, Dynatrace repurchased 0.79 million shares for approximately&nbsp;$43 million&nbsp;under its&nbsp;$500 million&nbsp;share repurchase program.
Q1 Outlook:&nbsp;Dynatrace expects revenue of $465.00 million-$470.00 million (<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus</a> $454.51 million). Dynatrace expects adjusted EPS of&nbsp;$0.37-$0.38 (consensus estimate $0.35).
2026 Outlook:&nbsp;Dynatrace expects revenue of $1.950 billion-$1.965 billion versus the analyst consensus of $1.940 billion. ARR is expected to be $1.975 billion-$1.990 billion.
Dynatrace expects adjusted EPS of $1.56-$1.59 versus the consensus estimate of $1.54.
Price Action: DT shares traded higher by 4.8% at $53.00 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45379380/can-corning-broadcom-deal-transform-ais-data-center-future" target="_blank" rel="noreferrer noopener">Can Corning-Broadcom Deal Transform AI&#8217;s Data Center Future?</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Dynatrace Delivers Double Beat, Raises The Bar For 2026

ANTA

Antalpha Platform Shares Halted On Circuit Breaker To The Upside At $16.51/Share

RBC Capital analyst Brian Abrahams reiterates Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Sector Perform and maintains $1.5 price target.

Price Target

Reiteration

Analyst Ratings

APLT

RBC Capital Reiterates Sector Perform on Applied Therapeutics, Maintains $1.5 Price Target

Solana (SOL) climbed <a href="https://www.benzinga.com/money/how-to-buy-solana#:~:text=Make%20Your%20Purchase&amp;text=To%20complete%20the%20transaction%2C%20head,you%20would%20like%20to%20purchase.">6.2% over 24 hours to $181.54</a>, outpacing the broader crypto market&#8217;s 12.7% uptick this week. The push leaves SOL up 23.4% on the week, and 37.14% over the past month, according to CoinMarketCap.
The surge comes on the heel of the U.S. Securities and Exchange Commission&#8217;s (SEC) delay of its decision on Grayscale&#8217;s proposed Solana ETF, signaling renewed bullish momentum in the wake of improving on‑chain fundamentals, ecosystem growth, and growing investor appetite.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
According to BeInCrypto, the SEC&#8217;s filing emphasized that the deferral &#8220;does not indicate any conclusions&#8221; and invited public comment on the proposed rule change—muting immediate price fallout as analysts expect approval later this year.
Meanwhile, big players are quietly stacking up their SOL stashes. Nasdaq‑listed DeFi Development Corp. announced that it added 172,670 SOL (about $23.6 million at an average $136.81 price) to its treasury, bringing its total holdings to nearly 595,000 SOL (worth $102.7 million). It&#8217;s the firm&#8217;s largest single acquisition to date, a concrete vote of confidence in Solana&#8217;s long‑term scalability and yield potential.
On the retail front, Solana&#8217;s meme‑coin scene is back in the spotlight. According to Decrypt, a trader turned a modest $332 wager on Gooncoin (a Solana‑based meme token) into $190,000 in a matter of days. It&#8217;s an extreme example, but it highlights how Solana&#8217;s low fees and fast block times have reignited speculative fervor. This also highlights how hype and liquidity are converging to fuel outsized short‑term returns within Solana&#8217;s fringe markets.
Digging deeper, the network&#8217;s health metrics underscore that this isn&#8217;t just hype. CoinMarketCap found that the daily active addresses are approaching multi‑month highs. Meanwhile, total value locked (TVL) in Solana‑based DeFi protocols continues to climb, exceeding that of all Ethereum layer 2s combined, a sign that genuine user adoption is underpinning the price moves, not just thrill‑seeking traders.
Solana isn&#8217;t stopping there. According to BitcoinInfoNews.com, the network is forging new speed‑optimized partnerships to bolster on‑chain payments, enabling fast, low‑cost transactions at scale. These alliances position SOL as more than a DeFi play, and usher it into real‑world use cases in micropayments and tokenized commerce.
Looking ahead, keep an eye on the $185 level as the next resistance hurdle. A sustained break above it could send SOL toward the $200 to $220 zone, while failure to hold current gains may trigger a dip back to the $172 to $175 range. The ultimate catalyst may be an eventual green light for a Solana ETF, and upcoming protocol upgrades, such as improvements to cross‑chain bridges and smart‑contract tooling.
Solana&#8217;s price action splashed with vibrant retail activity, institutional endorsements in the background, and a quietly strengthening network infrastructure, paints a compelling picture. While regulatory roadblocks may slow the pace, the pieces are falling into place for a bullish second half of 2025.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Solana Price Jumps 6% amid ETF delay and meme-coin mania

WIIM

Hyperfine shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 sales guidance below estimates. Also, Wells Fargo maintained an Equal-Weight rating on the stock and lowered its price target from $1.29 to $0.68.

IPOs

Antalpha Platform IPO Opens For Trade At $15.01/Share; IPO Priced At $12.80/Share On 3.85M Shares

Goldman Sachs analyst John Mackay maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $20 to $17.5.

Goldman Sachs Maintains Buy on Venture Global, Lowers Price Target to $17.5

ELMD

Electromed shares are trading lower after the company reported worse-than-expected Q3 sales results.

VRCA

Verrica Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Caitlin Burrows maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Buy and lowers the price target from $28 to $25.

SAFE

Goldman Sachs Maintains Buy on Safehold, Lowers Price Target to $25

LXRX

Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Goldman Sachs analyst Eric Sheridan maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $63 to $80.

RBLX

Goldman Sachs Maintains Neutral on Roblox, Raises Price Target to $80

SLND

Southland Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Outperform and maintains $10 price target.

ALLO

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Overweight and lowers the price target from $9 to $5.

SGMO

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Goldman Sachs analyst Will Nance maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $56 to $64.

HOOD

Goldman Sachs Maintains Buy on Robinhood Markets, Raises Price Target to $64

PTIX

Protagenic Therapeutics shares are trading lower. The company reported Q1 financial results.

WATT

Energous shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) with a Buy and lowers the price target from $20 to $18.

OLMA

Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $18

Fintech

Commodities

Press Releases

AGM Group Holdings Inc. Enters into Partnership Agreement with Nowlit to Facilitate Expansion in AI and Crypto Markets

AGM Group Holdings Inc. Announces Investment in Bitcoin Mining Equipment

AGM Group Holdings Inc. Announces Strategic Partnership with Canada's Nowlit to Expand High-Performance Computing Capabilities

AGM Group Holdings Inc. Highlights Strategic Growth and Future Initiatives in AI and Cryptocurrency

AGM Group Holdings Inc. Announces Strategic Partnership with HashBeaver to Drive Blockchain and AI Innovation

AGM Group Holdings Inc. Announces Pricing of $5.4 Million Public Offering

AGM Group Holdings Inc. Announces Closing of $5.4 Million Offering

AGM Group Holdings Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Requirements

AGM Group Holdings Inc. Receives Staff Determination Notice from Nasdaq and Plans to Appeal

Comments

AGM Gr Hldgs

Noticias

Últimas noticias sobre AGM Gr Hldgs (NASDAQ:AGMH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL